Immune-checkpoint inhibitors are widely used for lung cancer treatment [1]; therefore, the number of studies on the effects of estrogen on tumor immunity in lung cancer is increasing and data analyses using public databases have shown that ER and/or PgR expression in cancer tissues correlate with immune cell infiltration. Here, ESR1 is linked to lung carcinoma.